232 related articles for article (PubMed ID: 31161798)
1. The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Loutradis C; Papadopoulou E; Theodorakopoulou M; Karagiannis A; Sarafidis P
Future Med Chem; 2019 Jun; 11(11):1285-1303. PubMed ID: 31161798
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
3. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
[TBL] [Abstract][Full Text] [Related]
4. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
Wilcox CS
Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
7. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
8. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T
Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Nathan KT; Ahmed-Sarwar N; Werner P
Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 inhibitors as cardio-renal protective agents.
Caruso I; Giorgino F
Metabolism; 2022 Feb; 127():154937. PubMed ID: 34808144
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
14. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
Santos LL; Lima FJC; Sousa-Rodrigues CF; Barbosa FT
Rev Assoc Med Bras (1992); 2017 Jul; 63(7):636-641. PubMed ID: 28977090
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Mende CW
Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
Patoulias D; Imprialos K; Stavropoulos K; Athyros V; Doumas M
Curr Clin Pharmacol; 2018; 13(4):261-272. PubMed ID: 30084335
[TBL] [Abstract][Full Text] [Related]
17. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
18. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
19. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
[TBL] [Abstract][Full Text] [Related]
20. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
